Syn­thet­ic DNA play­er Touch­light scores $60M round to more than triple man­u­fac­tur­ing ca­pac­i­ty as mR­NA gets hot

With the twin au­tho­riza­tions of Pfiz­er/BioN­Tech’s and Mod­er­na’s mR­NA vac­cines for Covid-19 late last year, the mar­ket for start­ing ma­te­ri­als for that type of shot …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER